Where to buy Tafasitamab

Tafasitamab, trade nameMonjuvi, is a drug used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including low-grade lymphoma. It is a humanized Fc-modified cytolytic CD19 antibody that was approved for medical use in the United States in July 2020 and the European Union in August 2021, and is considered a first-in-class drug by the U.S. Food and Drug Administration (FDA).

The efficacy of tafracetamumab versus lenalidomide was evaluated in the L-MIND trial, in which patients received tafracetamumab 12 mg/kg intravenously with lenalidomide (25 mg orally on days 1-21 of each 28-day cycle) for up to 12 cycles, followed by tafracetamumab as monotherapy. The most common side effects of tafracetamumab are low blood counts, fatigue, diarrhea, cough, fever, swelling of the limbs, upper respiratory tract infection, and decreased appetite.

Tafaracetam's single-origin generic drug has not yet been launched in China, so it is not included in medical insurance. Domestic patients cannot yet purchase this drug. There are European and American versions of Tafaracetam's single-antigen drugs marketed overseas. The American version's specificationsThe price per box of 200 mg may be around 20,000 yuan, and the price of the European version's 200 mg box may be around 10,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same, but the price is more expensive. Currently, there is no generic version of Tafaracetam on the market. For more drug information and specific prices, please consult a medical consultant.